As a society dependent on technology and information, “false alarms” have become commonplace. Smoke detectors, invaluable as they are, alarm just the same whether there is burnt toast or a blazing housefire. In the medical field, incidental detection of, for instance, a pancreatic cyst can be found in 40–50% of persons undergoing abdominal imaging, fortunately often being a “false alarm”.1 A similar story has unfolded with high-resolution manometry (HRM). According to Chicago Classification version 3.0 (CCv3.0), an elevated lower oesophageal sphincter (LES) median integrated relaxation pressure (IRP) in the setting of preserved oesophageal body peristalsis on HRM met diagnosis for oesophagogastric junction (EGJ) outflow obstruction (EGJOO).2–4 Under this definition, 5–24% of all comers undergoing HRM met criteria for EGJOO.4–9 However, akin to shortcomings of a smoke detector, HRM as a single diagnostic test cannot reliably distinguish between true dysfunction across the LES with clinically meaningful and actionable EGJOO from those without. In fact, 32–94% of those who met CCv3.0 criteria for EGJOO but did not undergo treatment or intervention experienced symptomatic improvement over time.5–9 However, some patients with manometric EGJOO underwent invasive therapy when unneeded or not indicated.
These limitations were a key impetus for reframing EGJOO and the HRM protocol in CC version 4.0 (CCv4.0). The standard protocol in CCv4.0 moves beyond sole evaluation of deglutitive LES relaxation in the supine position to also evaluating the IRP in an upright position as well as with provocation. According to CCv4.0, the manometric diagnosis of EGJOO requires an elevated IRP in both supine and upright positions along with intrabolus pressurization. However, and also according to CCv4.0, manometric EGJOO is always inconclusive and requires additional data points including presence of clinical symptoms of obstruction as well as corroboration of LES obstruction on a non-HRM test such as timed barium oesophagram (TBE) or functional lumen imaging probe.4
Visaggi and colleagues examined the impact of these new diagnostic requisites on the prevalence of EGJOO.10 They identified that CCv4.0 diagnostic criteria (HRM metrics, symptoms, and TBE findings) yield higher specificity for EGJOO with an impressive 6-fold reduction (from 7.2% to 1.2%) of EGJOO prevalence. Further, they identified a lack of abnormal TBE in those without obstructive symptoms, justifying the requirement for obstructive symptoms for EGJOO in CCv4.0. They also demonstrated that a higher median rapid drink challenge (RDC)-IRP, specifically 16.7 mmHg, is predictive of conclusive EGJOO by CCv4.0 criteria.10
These data highlight the many ways that the updated HRM protocol and definition of EGJOO are a large leap forward in minimizing “false alarms”. Importantly, these updates in CCv4.0 promote a higher level of rigour and confidence in the manometric assessment of LES relaxation, and challenge us to think beyond the manometry study, particularly before intervention. Visaggi et al have further highlighted the potential for RDC-IRP as a surrogate for TBE, which may reduce requirements for additional testing for clinically conclusive EGJOO in future iterations of CC.
Figure.
Reframing the definition of EGJOO to Reduce False Alarms. The updates in CCv4.0 including increased data points to assess for LES obstruction on HRM, requirement of obstructive symptoms and corroboration of LES obstructive physiology on a non-HRM test have led to less “false alarms” of EGJOO diagnosis.
Grant Support:
T32 NIH Grant 5T32DK007202–44 (Ghosh, PI); NIH K23 DK125266 (Yadlapati, PI)
Abbreviations:
- HRM
High resolution manometry
- LES
Lower esophageal Sphincter
- CC
Chicago Classification
- IRP
Integrated relaxation pressure
- EGJ
Esophagogastric junction
- EGJOO
EGJ outflow obstruction
- TBE
Timed barium esophagram
- RDC
Rapid drink challenge
Footnotes
Conflicts of Interest:
EL: None
RY: Consultant: Medtronic (Institutional), Ironwood Pharmaceuticals (Institutional), Phathom Pharmaceuticals, StatDataLink, Medscape. Research support: Ironwood Pharmaceuticals; Advisory Board with Stock Options: RJS Mediagnostix
References
- 1.Kromrey ML, Bülow R, Hübner J, Paperlein C, Lerch MM, Ittermann T, Völzke H, Mayerle J, Kühn JP. Prospective study on the incidence, prevalence and 5-year pancreatic-related mortality of pancreatic cysts in a population-based study. Gut. 2018. Jan;67(1):138–145. doi: 10.1136/gutjnl-2016-313127. Epub 2017 Sep 6. PMID: 28877981. [DOI] [PubMed] [Google Scholar]
- 2.Yadlapati R, Kahrilas PJ, Fox MR, Bredenoord AJ, Prakash Gyawali C, Roman S, Babaei A, Mittal RK, Rommel N, Savarino E, Sifrim D, Smout A, Vaezi MF, Zerbib F, Akiyama J, Bhatia S, Bor S, Carlson DA, Chen JW, Cisternas D, Cock C, Coss-Adame E, de Bortoli N, Defilippi C, Fass R, Ghoshal UC, Gonlachanvit S, Hani A, Hebbard GS, Wook Jung K, Katz P, Katzka DA, Khan A, Kohn GP, Lazarescu A, Lengliner J, Mittal SK, Omari T, Park MI, Penagini R, Pohl D, Richter JE, Serra J, Sweis R, Tack J, Tatum RP, Tutuian R, Vela MF, Wong RK, Wu JC, Xiao Y, Pandolfino JE. Esophageal motility disorders on high-resolution manometry: Chicago classification version 4.0©. Neurogastroenterol Motil. 2021. Jan;33(1):e14058. doi: 10.1111/nmo.14058. PMID: 33373111; PMCID: PMC8034247. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Kahrilas PJ, Bredenoord AJ, Fox M, Gyawali CP, Roman S, Smout AJ, Pandolfino JE; International High Resolution Manometry Working Group. The Chicago Classification of esophageal motility disorders, v3.0. Neurogastroenterol Motil. 2015. Feb;27(2):160–74. doi: 10.1111/nmo.12477. Epub 2014 Dec 3. PMID: 25469569; PMCID: PMC4308501. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Bredenoord AJ, Babaei A, Carlson D, Omari T, Akiyama J, Yadlapati R, Pandolfino JE, Richter J, Fass R. Esophagogastric junction outflow obstruction. Neurogastroenterol Motil. 2021. Sep;33(9):e14193. doi: 10.1111/nmo.14193. Epub 2021 Jun 12. PMID: 34120375. [DOI] [PubMed] [Google Scholar]
- 5.Perez-Fernandez MT, Santander C, Marinero A, Burgos-Santamaría D, Chavarría-Herbozo C. Characterization and follow-up of esophagogastric junction outflow obstruction detected by high resolution manometry. Neurogastroenterol Motil. 2016;28:116–126. [DOI] [PubMed] [Google Scholar]
- 6.van Hoeij FB, Smout AJ, Bredenoord AJ. Characterization of idiopathic esophagogastric junction outflow obstruction. Neurogastroenterol Motil. 2015;27:1310–1316 [DOI] [PubMed] [Google Scholar]
- 7.Schupack D, Katzka DA, Geno DM, Ravi K. The clinical significance of esophagogastric junction outflow obstruction and hypercontractile esophagus in high resolution esophageal manometry. Neurogastroenterol Motil. 2017;29:1–9. [DOI] [PubMed] [Google Scholar]
- 8.Song BG, Min YW, Lee H, et al. Combined multichannel intraluminal impedance and high-resolution manometry improves detection of clinically relevant esophagogastric junction outflow obstruction. J Neurogastroenterol Motil. 2019;25:75–81 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Yadlapati R, Pandolfino JE, Fox MR, Bredenoord AJ, Kahrilas PJ. What is new in Chicago Classification version 4.0? Neurogastroenterol Motil. 2021. Jan;33(1):e14053. doi: 10.1111/nmo.14053. Epub 2020 Dec 19. PMID: 33340190; PMCID: PMC8098672. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Visaggi P, Ghisa M, Del Corso G, Svizzero FB, Mariani L, Tolone S, et al. Chicago classification v4.0 protocol improves specificity and accuracy of diagnosis of oesophagogastric junction outflow obstruction. Aliment Pharmacol Ther. 2022; 00: 1–8. 10.1111/apt.17101 [DOI] [PMC free article] [PubMed] [Google Scholar]

